Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.50 |
| ▸ | CYP11B1 | P15538 | 12/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 12/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.36 |
| ▸ | KHK | P50053 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | EIF4A3 | P38919 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | KDM5A | P29375 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13953846 | 0.92 | TRPV4 (0.45) | TRPV4CYP11B1CYP11B2ADRB2ADRB1 | |
| SCHEMBL27411714 | 0.89 | TRPV4 (0.47) | TRPV4CYP11B1CYP11B2ADRB2ADRB1 | |
| SCHEMBL26137538 | 0.88 | TRPV4 (0.36) | TRPV4CYP11B1CYP11B2ADRB2ADRB1 | |
| SCHEMBL16122320 | 0.88 | TRPV4 (0.45) | TRPV4CYP11B1CYP11B2ADRB2ADRB1 | |
| SCHEMBL18068019 | 0.88 | TRPV4 (0.41) | TRPV4CYP11B1CYP11B2ADRB2ADRB1 | |
| SCHEMBL12041224 | 0.85 | TRPV4 (0.42) | TRPV4CYP11B1CYP11B2ADRB2ADRB1 | |
| SCHEMBL25194511 | 0.84 | TRPV4 (0.47) | TRPV4CYP11B1CYP11B2ADRB2ADRB1 | |
| SCHEMBL14433590 | 0.84 | TRPV4 (0.42) | TRPV4CYP11B1CYP11B2ADRB2ADRB1 | |
| SCHEMBL12186140 | 0.84 | TRPV4 (0.38) | TRPV4CYP11B1CYP11B2ADRB2ADRB1 | |
| SCHEMBL17946968 | 0.82 | ALDH1A1 (0.43) | TRPV4CYP11B2KHKAREIF4A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227426-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-07-20 | — | — | US | disclosed |
| US-9809583-B2 | Oxazolidine-based compound and selective androgen receptor agonist comprising same | DONG-A ST CO., LTD. (KR) | 2017-11-07 | — | — | US | disclosed |
| US-20170050955-A1 | OXAZOLIDINE-BASED COMPOUND AND SELECTIVE ANDROGEN RECEPTOR AGONIST COMPRISING SAME | DONG-A ST CO., LTD. (KR) | 2017-02-23 | — | — | US | disclosed |
| US-8293729-B2 | Compounds, pharmaceutical composition and methods relating thereto | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-23 | — | — | US | disclosed |
| US-8293729-B2 | Compounds, pharmaceutical composition and methods relating thereto | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-23 | — | — | US | disclosed |
| US-20110166116-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-07 | — | — | US | disclosed |
| US-20110166116-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170050955-A1 | OXAZOLIDINE-BASED COMPOUND AND SELECTIVE ANDROGEN RECEPTOR AGONIST COMPRISING SAME | AR, SHBG, MUSK | TRPV4 1690/4885CYP11B1 71/4885CYP11B2 49/4885 |
| US-20230227426-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE | HIF1AN, EGLN3, PHF20 | TRPV4 3545/4885CYP11B1 436/4885CYP11B2 475/4885 |
| US-20110166116-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO | MC2R, REN, CYP11B2 | TRPV4 3119/4885CYP11B1 5/4885CYP11B2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.